Additionally, the novel finding is that PTEN loss or KRAS activation individually is sufficient to promote cellular persistence reminiscent of tumor cell dormancy, has potential implication for cancer dormancy and reoccurrence risk. The gene discussed is KRAS; the disease is cancer.